BOEHRINGER INGELHEIM FIRST PHARMA GIANT BENEFITTING FROM CHINA’S POLICY BREAKTHROUGH ON CMO
March 1st, 2016
After China’s National People's Congress in late 2015 legalised biopharma contract manufacturing organisation (CMO) in mainland China, German pharmaceutical giant Boehringer Ingelheim has confirmed to the Manufacturing Chemist that its subsidy, Boehringer Ingelheim China, is working at China’s first biopharma CMO pilot project.
“Under the [new] marketing authorization holder system, drug holders are allowed to manufacture the drugs on their own or choose contract manufacturers instead. Contract manufacturing will therefore help separate drug marketing ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.